Skip to main content

NASDAQ:KMDA - Kamada Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 79.74 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.12
▲ +0.04 (0.66%)
1 month | 3 months | 12 months
Get New Kamada Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KMDA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KMDA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.00
▲ +79.74% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Kamada in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 79.74% upside from the last price of $6.12.

Buy

The current consensus among 2 investment analysts is to buy stock in Kamada. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/14/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$7.00 ➝ $11.00High
i
8/13/2020HC WainwrightReiterated RatingBuy$11.00Low
i
Rating by Andrew Fein at HC Wainwright
5/19/2020HC WainwrightReiterated RatingBuy$11.00High
i
Rating by Andrew Fein at HC Wainwright
12/23/2019HC WainwrightReiterated RatingBuy$11.00Medium
i
8/7/2019HC WainwrightReiterated RatingBuy$11.00Low
i
Rating by A. Fein at HC Wainwright
5/17/2019Chardan CapitalReiterated RatingBuy$7.00Low
i
2/14/2019HC WainwrightReiterated RatingBuy$11.00Low
i
Rating by A. Fein at HC Wainwright
8/8/2018HC WainwrightSet Price TargetBuy$11.00Low
i
Rating by Andrew Fein at HC Wainwright
2/8/2018HC WainwrightReiterated RatingBuyHigh
i
Rating by A. Fein at HC Wainwright
2/2/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$7.00Low
i
Rating by K. Nakae at Chardan Capital
10/12/2017Jefferies Financial GroupReiterated RatingBuy$7.00N/A
i
8/2/2017Jefferies Financial GroupReiterated RatingBuy$9.00 ➝ $7.00Low
i
5/17/2017Jefferies Financial GroupReiterated RatingBuy$9.00High
i
4/12/2017Jefferies Financial GroupReiterated RatingBuy$8.00High
i
2/7/2017HC WainwrightSet Price TargetBuy$10.00N/A
i
11/11/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
9/3/2016HC WainwrightReiterated RatingBuy$10.00N/A
i
8/31/2016Jefferies Financial GroupReiterated RatingBuy$7.00N/A
i
(Data available from 5/8/2016 forward)
Kamada logo
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; AeroBika, an OPEP device; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $6.12
$6.03
$6.13

50 Day Range

MA: $6.14
$6.02
$6.39

52 Week Range

Now: $6.12
$5.78
$13.33

Volume

45,229 shs

Average Volume

176,757 shs

Market Capitalization

$272.46 million

P/E Ratio

12.75

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Kamada?

The following Wall Street analysts have issued stock ratings on Kamada in the last twelve months: Chardan Capital, HC Wainwright, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for KMDA.

What is the current price target for Kamada?

2 Wall Street analysts have set twelve-month price targets for Kamada in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 79.7%. Chardan Capital has the highest price target set, predicting KMDA will reach $11.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $11.00 for Kamada in the next year.
View the latest price targets for KMDA.

What is the current consensus analyst rating for Kamada?

Kamada currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KMDA will outperform the market and that investors should add to their positions of Kamada.
View the latest ratings for KMDA.

What other companies compete with Kamada?

How do I contact Kamada's investor relations team?

Kamada's physical mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company's listed phone number is 972-8940-6472 and its investor relations email address is [email protected] The official website for Kamada is www.kamada.com.